Main Article Content
Leukemia is a common malignancy of childhood. Leukemias are group of malignant disorders of the haematopoietic tissues that are characteristically associated with increased numbers of leucocytes in bone marrow and/or peripheral blood. The aetiology of leukemia is unknown but several lines of evidence do suggest that the disease is a result of interactions between several factors for example: viral infections, ionizing radiations, chemicals and genetic factors. The incidence of ALL varies, and depends on age, sex and race. Antineoplastic agents (cytotoxic drugs) are used in the treatment of malignant diseases when radiotherapy and surgery are not possible or they are not effective. This study aims to evaluate some of biochemical parameters in children with Acute Lymphoblastic Leukemia. The results indicated that the value of parameters tested varies according to type of test (i.e. some higher than normal, some less than normal).
Matrials & Methods: Eighteen pediatric acute lymphoblastic leukemia children were included in this study. All were subjected to γ-tocopherol, methotrexate, vincristine, and 6-mercaptopurine chemotherapy treatment. Serum fasting glucose, total bilirubin, direct bilirubin, total protein, albumin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase levels were measured using autoanalyser device.
Results: Of eighteen pediatric patients, two (11.11%) were hypoglycemic (22.00±1.00mg/dL), two (11.11%) with high direct bilirubin (0.50±0.00mg/dL), six (33.33%) with low total protein (3.83±0.85gm/dL), eight (44.44%) with low albumin (2.47±0.41gm/dL), four (22.22%) with low alkaline phosphatase (20.50±11.83U/L), six (33.33%) with high alanine aminotransferase (136.66±37U/l)., and ten (55.56%) with high aspartate aminotransferase (238.60±39.15IU/L).
Conclusions: malignancy of disease and chemotherapy treatment negatively affected biochemical levels included in this study, liver function, and nutritional status of patients.
Baninhashem A, Ghasemi A, Ghaemi N, Moazzen N, Amirabadi A. Prevalence of transient hyperglycemia and diabetes mellitus in pediatric patients with acute leukemia. Iran J Ped Hematol Oncol. 2014:4(1):5-10.
Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med, 2006: 354(2):166-178.
Karakkattu, J. and Roshni, P. Etiology for liver diseases in pediatric population. Asian J Pharm Clin Res, 2017;10(1):91-94.
Khan A, Sheikh M, Intekhhab K. Effect of hypoproteinemia on treatment outcome in children with acute lymphoblastic leukemia. Journalof Ayub Medical College. 2006;18(2):53-55.
Antillon F, Maselli T, Gracia T, Rossi E, Sala A. Nutritional status of children during treatment for acute lymphoblastic leukemia in the Central American Pediatric Hematology Oncology Association: preliminary data from Guatemala. Pediatric Blood Cancer. 2008;50:502-505.
Berdanier C, Dwyer J, Feldman E. Handbook of nutrition and food. 2nd edition. 2008;1211-1221.
Mihaela C., Despina, B., Adrienne, H. and Diana, M. Nutritional parameters in children with acute leukemia. Acta Medica Marisiensis, 2011:57(1):1-12.
Hunger, S. and Mullighan, C. Acute lymphoblastic leukemia in children. N ENGL J MED, 2015: 373(16):1541-1552.
Liu GJ, Cimmino L, Jude JG, Hu Y, Witkowski MT, McKenzie MD, Kartal-Kaess M, Best SA, Tuohey L, Liao Y, Shi W, Mullighan CG, Farrar MA, Nutt SL, Smyth GK, Zuber J, Dickins RA. Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes Dev, 2014: 28(112):1337-1350.
Blanco E, Beyene J, Maloney AM, Almeida R, Ethier MC, Winick N, Alexander S, Sung L. Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2012;53(5):878-885.
Halton J, Nazir D, McQueen M, Barr R. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer. 1998;83(2):379-384.
Schmiegelow K, Nielsen S, Frandsen T, Nerstine J. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol, 2014;36(7): 503-517.
Childhood ALL Collaborative Group. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukemia: overview of 42 trials involving 12000randomised children. Lancet. 1996: 347:1783-1788.
Escherich G, Horstmann MA, Zimmermann M, Janka-Schaub GE. Cooperative study group for childhood acute lymphoblastic leukemia (COALL): long-term results of trials 82, 85, 89, 92 and 97. Leukemia. 2010; 24:298-308.
Schmiegelow K. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol, 1991:8:301-312.
Halonen P, Salo MK, Schmiegelow K, Makipernaa A. Investigation of the mechanisms of therapy-related hypoglycemia in children with acute lymphoblastic leukemia. Acta Paediatr. 2003;92:37-42.
(SAS) SAS. SAS/STAT users guide for personal computer. Release 9.1.. SAS Institute, Inc., Cary, N.C., USA; 2010.
Hagag A, Elgamsy M, EL-Asy H, Mabrouk M. Protective role of silymarin on hepatic and renal toxicity induced by MTX based chemotherapy in children with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2016;8(1):e2016043.
Navarro VJ. Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739.
Giannini E, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ. 2005;172(3):367-379.
Burkitt HG, Young B, Heath JW. Wheather's functional histology: A text and colour atlas. 3rd edition. Edinburgh: Churchill Livingston; 1993.
Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology, 2002;123(4):1367-1384.
Fishman WH. Alkaline phosphatase isoenzymes: recent progress. Clin Biochem. 1990;23(2):99-104.
Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med, 2000;109(2):109-113.
Berk PD, Noyer C. Clinical chemistry and physiology of bilirubin. Seminar Liver Dis. 1994;4(4):346-355.
Bonis PA, Tong MJ, Blatt LM, Conrad A, Griffith JL. A predictive model for the development of hepatocellular carcinoma, liver failure, or liver transplantation for patients presenting to clinic with chronic hepatitis C. Am J Gastroenterol. 1999;94(6):1605-1612.